血浆D-二聚体检测对甲状腺癌患者的临床意义  

Clinical Significance of Plasma D-dimer Testing in Patients with Thyroid Cancer

作　　者：宋文炜[1] 

机构地区：[1]徐州矿物集团总医院检验科

出　　处：《现代检验医学杂志》2016年第6期138-140,共3页Journal of Modern Laboratory Medicine

摘　　要：目的：观察血浆D-二聚体检测在甲状腺癌患者手术前后及分期的变化，探讨其对甲状腺癌患者的临床意义。方法选择60例甲状腺癌患者，同期甲状腺良性病变患者50例，健康体检者52例，观察各组空腹血浆 D-二聚体水平，并进行比较；同时，对甲状腺癌患者术后血浆 D-二聚体水平进行监测。结果甲状腺癌患者血浆 D-二聚体水平（2.01±0.75 mg／L）明显高于良性组（0.63±0.31 mg／L）及健康体检组（0.28±0.12 mg／L），差异具有统计学意义（t＝11.72，11.06，均P＜0.0001）；血浆D-二聚体水平与甲状腺癌恶性程度相关，分期Ⅲ～Ⅳ期患者血浆 D-二聚体水平明显高于 l～Ⅱ期患者（t＝9.83，P＜0.05）；在术后一周甲状腺癌患者D-二聚体水平明显下降。结论 D-二聚体水平在甲状腺癌患者手术前后有明显变化，且与临床分期有关，可作为甲状腺癌患者治疗评价及疾病监测、预后的指标，具有临床应用价值。Objective To observe the levels of plasma D-dimer in patients with thyroid cancer before and after surgery,and explore its clinical significance.Methods 60 patients with thyroid cancer,50 patients with thyroid benign lesions and 52 healthy controls were chosen in the study.D-dimer levels in different groups were tested.At the same time,for patients with thyroid carcinoma,the postoperative levels of plasma D-dimer were monitored.Results Level of plasma D-dimer in patients with thyroid cancer （2.01±0.75 mg/L）was significantly higher than those in thyroid benign lesions group （0.63±0.31 mg/L）and healthy control （0.28±0.12 mg/L）（t=11.72,11.06,all P〈0.000 1）.Plasma D-dimer levels were corelated with malignant degrees of thyroid carcinoma,patients in stageⅢ-Ⅳ had a higher level of plasma D-dimer than I-Ⅱperiod pa-tients （t=9.83,P〈0.05）.The postoperative level of D-dimer in patients with thyroid cancer were significantly decreased. Conclusion D-dimer levels were obviously changed in thyroid cancer patients before and after surgery,and was corelated with clinical stages.Thus,it could be used as an evaluation index of treatment outcome and a prognostic factor for patients with thyroid cancer.

关 键 词：D-二聚体 甲状腺癌 临床分期 

分 类 号：R736.1[医药卫生—肿瘤] R730.43[医药卫生—临床医学]